1. AB0955 Tildrakizumab efficacy over time by week 28 response levels in two phase 3 clinical trials in patients with chronic plaque psoriasis. (12th June 2018) Authors: Blauvelt, A.; Sofen, H.; Papp, K.; Gooderham, M.; Zhao, Y.; Lowry, S.; Mendelsohn, A.; Parno, J.; Li, Q.; Rosa, C.L.; Reich, K. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 1602 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗